The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khammad V.A.

P.A. Herzen Moscow Oncology Research Institute, Moscow, Russia;
Department of Oncology and Radiology and Nuclear Medicine, Peoples’ Friendship University of Russia, Moscow, Russia

Zaĭtsev A.M.

FGU Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Minzdravsotsrazvitiia Rossii, Moskva

Kirsanova O.N.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossiii

Kharchenko N.V.

Department of Oncology and Roentgenology and Radiology, Medical Institute, Peoples’ Friendship University of Russia, Ministry of Education and Science of the Russian Federation, Moscow, Russia

Zapirov G.M.

Department of Oncology and Roentgenology and Radiology, Medical Institute, Peoples’ Friendship University of Russia, Ministry of Education and Science of the Russian Federation, Moscow, Russia

Kisar'ev S.A.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva;
Otdelenie neĭrokhirurgii Nizhegorodskogo nauchno-issledovatel'skogo instituta travmatologii i ortopedii

Kobyletskaya T.M.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

The role of the deficient DNA mismatch repair system as a factor of sensitivity to targeted therapy for glioblastoma multiforme

Authors:

Khammad V.A., Zaĭtsev A.M., Kirsanova O.N., Kharchenko N.V., Zapirov G.M., Kisar'ev S.A., Kobyletskaya T.M.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2019;8(5): 379‑384

DOI: 10.17116/onkolog20198051379

Read: 2075 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF THE DEFICIENT DNA MISMATCH REPAIR SYSTEM AS A FACTOR OF SENSITIVITY TO TARGETED THERAPY FOR GLIOBLASTOMA MULTIFORME
THE ROLE OF THE DEFICIENT DNA MISMATCH REPAIR SYSTEM AS A FACTOR OF SENSITIVITY TO TARGETED THERAPY FOR GLIOBLASTOMA MULTIFORME

To cite this article:

Khammad VA, Zaĭtsev AM, Kirsanova ON, Kharchenko NV, Zapirov GM, Kisar'ev SA, Kobyletskaya TM. The role of the deficient DNA mismatch repair system as a factor of sensitivity to targeted therapy for glioblastoma multiforme. P.A. Herzen Journal of Oncology. 2019;8(5):379‑384. (In Russ.)
https://doi.org/10.17116/onkolog20198051379

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Glioblastoma multiforme (GBM) is one of the most aggressive and common tumors of the central nervous system. It accounts for approximately 50% of gliomas in all age groups. Despite a variety of current treatment regimens (surgical intervention with adjuvant chemotherapy and radiotherapy), GBM is still a deadly disease with an extremely poor prognosis: the overall median survival is 14.6 months after the date of diagnosis. The unfavorable prognostic factors of GBM include somatic mutations in the MSH6 gene, since they are associated with an acquired resistance of tumor cells to the alkylating agent temozolomide and significantly increase the risk of a relapse. GBM is less commonly observed in infants than in adults and is characterized by the increased amplification of MYC, MYCN and PDGFRA genes. However, a detailed study of molecular alterations in biallellic mismatch repair deficiency syndrome (bMMRD) has opened new opportunities for the successful treatment of GBM with immune checkpoint inhibitors in pediatrics.

Keywords:

glioblastoma multiforme
somatic mutations in the MSH6 gene
temozolomide resistance
immune checkpoint inhibitors

Authors:

Khammad V.A.

P.A. Herzen Moscow Oncology Research Institute, Moscow, Russia;
Department of Oncology and Radiology and Nuclear Medicine, Peoples’ Friendship University of Russia, Moscow, Russia

Zaĭtsev A.M.

FGU Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Minzdravsotsrazvitiia Rossii, Moskva

Kirsanova O.N.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossiii

Kharchenko N.V.

Department of Oncology and Roentgenology and Radiology, Medical Institute, Peoples’ Friendship University of Russia, Ministry of Education and Science of the Russian Federation, Moscow, Russia

Zapirov G.M.

Department of Oncology and Roentgenology and Radiology, Medical Institute, Peoples’ Friendship University of Russia, Ministry of Education and Science of the Russian Federation, Moscow, Russia

Kisar'ev S.A.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva;
Otdelenie neĭrokhirurgii Nizhegorodskogo nauchno-issledovatel'skogo instituta travmatologii i ortopedii

Kobyletskaya T.M.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Close metadata

References:

  1. Louis DN, Ohgaki H,Weistler OD, et al. WHO Classification of tumours of the central nervous system. Lyon: IARC, 2007. https://doi.org/10.1007/s00401-007-0243-4
  2. Utin AYu, Matsko DE, Olyushin VE. Neuroepithelial brain tumors (Neiroepitelial’nye opukholi golovnogo mozga). St. Petersburg: Sintez Buk, 2014.
  3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466. https://doi.org/10.1016/S1470-2045(09)70025-7
  4. Boyett J, Yates A, Gilles F, et al. When is a high-grade astrocytoma (HGA) not a HGA? Results of a central review of 226 cases of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and other-HGA (OTH-HGA) by five neuropathologists. Proc Am Soc Clin Oncol. 1998;17:526a.
  5. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma Multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(3-4):3-9. https://doi.org/10.22034/APJCP.2017.18.1.3
  6. Van Genugten JA, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol. 2010;96(2):249-257. https://doi.org/10.1007/s11060-009-9956-7
  7. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23(10):2372-2377. https://doi.org/10.1200/JCO.2005.00.331
  8. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009;27(23):3861-3867. https://doi.org/10.1200/JCO.2008.20.7944
  9. Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, et al. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastomas: single-center experience. Clin Neurol Neurosurg. 2009;111(8):679-682. https://doi.org/10.1016/j.clineuro.2009.06.013
  10. McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed paraffin-embedded astrocytomas. Lab Invest. 1998;78(5):643-644.
  11. Brent TP, von Wronski M, Pegram CN, Bigner DD. Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. Cancer Res. 1990;50(1):58-61.
  12. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-4199. https://doi.org/10.1200/JCO.2007.11.5964
  13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. https://doi.org/10.1056/NEJMoa043331
  14. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39-51. https://doi.org/10.1038/nrneurol.2009.197
  15. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in glioblastoma multiforme. Pediatr Blood Cancer. 2007;48(4):403-407. https://doi.org/10.1371/journal.pone.0107558
  16. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15(14):4622-4629. https://doi.org/10.1158/1078-0432.CCR-08-3012
  17. Slean MM, Panigrahi GB, Ranum LP, Pearson CE. Mutagenic roles of DNA ‘repair’ proteins in antibody diversity and disease-associated trinucleotide repeat instability. DNA Repair (Amst). 2008;7(7):1135-1154. https://doi.org/10.1016/j.dnarep.2008.03.014
  18. Stark AM, Doukas A, Hugo HH, Mehdorn HM. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki-67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res. 2010;32(8):816-820. https://doi.org/10.1179/016164110X1264501351505
  19. Wieland M, Levin MK, Hingorani KS, Biro FN, Hingorani MM. Mechanism of cadmium-mediated inhibition of Msh2—Msh6 function in DNA mismatch repair. Biochemistry. 2009;48(40):9492-502. https://doi.org/10.1021/bi9001248
  20. Zhao YS, Hu FL, Wang F, Han B, Li DD, Li XW, Zhu S. Meta-analysis of MSH6 gene mutation frequency in colorectal and endometrial cancers. J Toxicol Environ Health A. 2009;72(11-12):690-697. https://doi.org/10.1080/15287390902841003
  21. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66(8):3987-3991. https://doi.org/10.1158/0008-5472.CAN-06-0127
  22. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-461. https://doi.org/10.1016/S1470-2045(08)70125-6
  23. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068. https://doi.org/10.1038/nature07385
  24. Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S. Novel MSH6 mutations in treatment — naive glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clin Cancer Res. 2014;20(18):4894-4903. https://doi.org/10.1158/1078-0432.CCR-13-1856
  25. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011;129(3):659-670. https://doi.org/10.1002/ijc.26083
  26. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res. 2008;14(15):4859-4868. https://doi.org/10.1158/1078-0432.CCR-07-4807
  27. Alonso M, Hamelin R, Kim M, Porwancher K, Sung T, Parhar P, Miller DC, Newcomb EW. Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res. 2001;61(5):2124-2128.
  28. Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin M, Kucherlapati R, Kolodner RD, Edelmann W. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell. 2004;6(2):139-150. https://doi.org/10.1016/j.ccr.2004.06.024
  29. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13(7):2038-2045. https://doi.org/10.1158/1078-0432.CCR-06-2149
  30. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336-2346. https://doi.org/10.1056/NEJMoa1508054
  31. Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: Suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J Med Genet. 2014;51(6):355-365. https://doi.org/10.1136/jmedgenet-2014-102284
  32. Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. Eur J Cancer. 2014;50(5):987-996. https://doi.org/10.1016/j.ejca.2013.12.005
  33. Durno CA, Aronson M, Tabori U, Malkin D, Gallinger S, Chan HS. Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer. 2012;59(4):652-656. https://doi.org/10.1002/pbc.24019
  34. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092-2099. https://doi.org/10.1200/JCO.2014.60.0379
  35. Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy success. Science. 2015;350(6257):158-159. https://doi.org/10.1126/science.aad4140
  36. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004-2012. https://doi.org/10.1200/JCO.2014.58.3708
  37. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017. https://doi.org/10.1056/NEJMoa1414428
  38. Errico A. Melanoma. CheckMate 067-Frontline nivolumab improves PFS alone or in combination with ipilimumab. Nat Rev Clin Oncol. 2015;12(8):435. https://doi.org/10.1038/nrclinonc
  39. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206-2211. https://doi.org/10.1200/JCO.2016.66.6552
  40. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-1615. https://doi.org/10.1158/1078-0432.CCR-10-2563
  41. MacDonald TJ, Vezina G, Stewart CF, Turner D, Pierson CR, Chen L, Pollack IF, Gajjar A, Kieran MW. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro Oncol. 2013;15(10):1438-1444. https://doi.org/10.1093/neuonc/not058
  42. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995;13(1):112-123.
  43. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-211. https://doi.org/10.1126/science.aad0095
  44. Srivastava PK, Duan F. Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunol Immunother. 2013;62(5):967-974. https://doi.org/10.1007/s00262-013-1422-x
  45. Yamauchi T, Ogawa M, Ueda T. Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. Mol Pharmacol. 2008;74(1):82-91. https://doi.org/10.1124/mol.107.041988
  46. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms — an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11(2):165-180. https://doi.org/10.1634/theoncologist.11-2-165
  47. Aquilina G, Ceccotti S, Martinelli S, Hampson R, Bignami M. N-(2-chloroethyl)-N0-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res. 1998;58(1):135-141.
  48. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420. https://doi.org/10.1158/1078-0432.CCR-09-1624
  49. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7:283ra53. https://doi.org/10.1126/scitranslmed.aaa7161
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.